L. P. Quirós and R. Ugalde, “Analysis of the budgetary impact of alemtuzumab as second-line therapy, compared to natalizumab and fingolimod, in patients previously treated with interferon beta 1b, diagnosed with active relapsing-remitting multiple sclerosis, treated in the Costa Rican social security fund”, Grhta, vol. 6, no. 1, Mar. 2019.